Linsitinib (OSI-906)

目录号:S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 1550.54 现货
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活,IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体,具有良好的代谢稳定性。OSI-906浓度为1μM时,完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖,包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系,EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XEcWlEPTB;MD6wNlgxPiEQvF2= NETHN2RUSU6JRWK=
KS-1 M{\Y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHflN5pKSzVyPUCuNFM5OzVizszN MojwV2FPT0WU
TE-11 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH0TWM2OD1yLkC3PFIzKM7:TR?= MoPxV2FPT0WU
EW-1 NH3nOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHBWJQ{UUN3ME2wMlA5PTh3IN88US=> NIfDRZpUSU6JRWK=
HMV-II MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TxbWlEPTB;MD6wPFg1PiEQvF2= MnXvV2FPT0WU
COLO-205 NUDhNYoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLxTWM2OD1yLkGwOFU1KM7:TR?= M3PEcnNCVkeHUh?=
ES1 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvPXog1UUN3ME2wMlExPjl4IN88US=> M3vsc3NCVkeHUh?=
GDM-1 NEjaN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoeyTWM2OD1yLkGzOlczKM7:TR?= NWXrN2w1W0GQR1XS
ML-2 NGnrbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[zdXM2UUN3ME2wMlE2QDl4IN88US=> NH;jcGVUSU6JRWK=
Saos-2 M{PXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjiemJCUUN3ME2wMlE3PTJ4IN88US=> MY\TRW5ITVJ?
NCI-H1355 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m5NGlEPTB;MD6xPFE{PSEQvF2= MV;TRW5ITVJ?
G-401 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PROmlEPTB;MD6xPFI{KM7:TR?= NGLJZW1USU6JRWK=
EW-16 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX3cZpKSzVyPUCuNVg4PzdizszN MYLTRW5ITVJ?
EW-7 NHjvWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O4XGlEPTB;MD6xPFg5OSEQvF2= M4TMcXNCVkeHUh?=
NCI-H727 NH;rfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fmNGlEPTB;MD6xPVc6PCEQvF2= MWfTRW5ITVJ?
LCLC-97TM1 M2LDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ToN2lEPTB;MD6yNFk2PSEQvF2= NF;Dd|dUSU6JRWK=
NCI-H650 MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn2TVlKSzVyPUCuNlE{QDRizszN MVLTRW5ITVJ?
NCI-H2122 MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX3TWM2OD1yLkKzNlk6KM7:TR?= MX\TRW5ITVJ?
SK-N-DZ MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:5ToJmUUN3ME2wMlI{Pjl6IN88US=> NGnv[IdUSU6JRWK=
HT-29 M3vEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfTTWM2OD1yLkK0NlQ5KM7:TR?= MorsV2FPT0WU
LB771-HNC NH;xeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm3V3B1UUN3ME2wMlI2QTF3IN88US=> M{Lu[XNCVkeHUh?=
HT-144 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXlTWM2OD1yLkK2NVkyKM7:TR?= MlXsV2FPT0WU
LAN-6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMk[zOFgh|ryP MYnTRW5ITVJ?
EW-18 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HTcWlEPTB;MD6yO|AxOSEQvF2= NV;0RXNmW0GQR1XS
LS-1034 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHKTWM2OD1yLkK3NVMzKM7:TR?= MUXTRW5ITVJ?
EW-11 NY[3RYN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG1TWM2OD1yLkK4OFMzKM7:TR?= NFSwemlUSU6JRWK=
SNU-C1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDFXZRKSzVyPUCuNlk{OTNizszN M2\lNXNCVkeHUh?=
RS4-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfSO|ZVUUN3ME2wMlM{PzV6IN88US=> Ml;KV2FPT0WU
ES4 NX\seZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzRTWM2OD1yLkSxNFM5KM7:TR?= M37pdHNCVkeHUh?=
COLO-320-HSR MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjPSXB1UUN3ME2wMlQyOzZ6IN88US=> NH\sdFNUSU6JRWK=
NB10 M2OyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTUNJVKSzVyPUCuOFU1OzdizszN NIrhd5BUSU6JRWK=
BFTC-905 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fHO2lEPTB;MD60Olc2QCEQvF2= M37CbHNCVkeHUh?=
A375 NGjLU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7HTWM2OD1yLkS3OlE4KM7:TR?= NWDoZXl6W0GQR1XS
SJRH30 NH3IWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn3e4NKSzVyPUCuOVA5OjJizszN MVjTRW5ITVJ?
NOS-1 MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvLTWM2OD1yLkWyNlY4KM7:TR?= M4Due3NCVkeHUh?=
SIG-M5 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjsZYZKSzVyPUCuOVM2PTdizszN Mm\6V2FPT0WU
DOK NIHSV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwNUW2JO69VQ>? MVHTRW5ITVJ?
NB69 M{TaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrKRWhMUUN3ME2wMlU5OjV5IN88US=> MU\TRW5ITVJ?
SK-NEP-1 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwNkCyN|Yh|ryP M1rtRnNCVkeHUh?=
SK-MM-2 NXTy[ZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TSR2lEPTB;MD62OVQ6OSEQvF2= M3fwcXNCVkeHUh?=
NCI-H358 M3zQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n3TWlEPTB;MD62O|A5OiEQvF2= NX\vdmxVW0GQR1XS
RH-1 NFnUNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHVWIlYUUN3ME2wMlc1QDV7IN88US=> NFexc2pUSU6JRWK=
NH-12 NUPFWYJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwN{[wOFYh|ryP NFTFU|ZUSU6JRWK=
TE-12 NXrpWVlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn20TWM2OD1yLke2OFg3KM7:TR?= NFnlZ|JUSU6JRWK=
COLO-668 NHvG[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ja[2lEPTB;MD64OFY3PiEQvF2= MoP6V2FPT0WU
PANC-08-13 NVTHdlJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwOE[zO|ch|ryP MlfHV2FPT0WU
HCC2998 M3PYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHnSWxnUUN3ME2wMlg5OjZ|IN88US=> NIeweFdUSU6JRWK=
ABC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwOUCzOVIh|ryP NEnXdWFUSU6JRWK=
ES6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwOUGwOlYh|ryP MXzTRW5ITVJ?
SNU-387 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnVeItWUUN3ME2wMlk6Ozl|IN88US=> MU\TRW5ITVJ?
CMK M2C1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXiTppKSzVyPUCuPVk6OjlizszN NFPI[W5USU6JRWK=
SJSA-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jSWWlEPTB;MT6wN|Y2OyEQvF2= NVriUGROW0GQR1XS
SIMA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOweJlrUUN3ME2xMlA3QDJ3IN88US=> NEnrN|RUSU6JRWK=
ES3 M2\uWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;4SW41UUN3ME2xMlEzOjl5IN88US=> NGrZbW1USU6JRWK=
IGROV-1 NX36V3VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwMUW0OFQh|ryP MoPMV2FPT0WU
MEL-JUSO NG\mV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q0dWlEPTB;MT6xOVc2QSEQvF2= MVvTRW5ITVJ?
T84 NIHJPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LXU2lEPTB;MT6yNFkyPCEQvF2= NIjmW2NUSU6JRWK=
CAL-85-1 NGHuPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnCOWVKSzVyPUGuNlMyOzhizszN MYjTRW5ITVJ?
RD M4nK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOzd5pKSzVyPUGuNlY1PTVizszN NV;zTmJbW0GQR1XS
TE-8 M2Lp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwM{G0OlIh|ryP MV\TRW5ITVJ?
L-363 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwM{SyNFgh|ryP MoLPV2FPT0WU
EKVX MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\DTWM2OD1zLkO0OVY5KM7:TR?= NYm2OmJGW0GQR1XS
SK-MEL-3 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoexTWM2OD1zLkS4OVU3KM7:TR?= MmDpV2FPT0WU
TGBC24TKB NX7Vc416T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPoeoY3UUN3ME2xMlUxOTl|IN88US=> NV3URYd5W0GQR1XS
NCI-H1770 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHYVG5xUUN3ME2xMlUyOTF|IN88US=> MVPTRW5ITVJ?
HuH-7 NGmxfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjrTWM2OD1zLk[wNFk5KM7:TR?= M{TxfnNCVkeHUh?=
HL-60 NWfBWHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT2NpF{UUN3ME2xMlY3QTJ6IN88US=> NVWzNlhDW0GQR1XS
TE-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwN{C5OFUh|ryP M{fpR3NCVkeHUh?=
LC-2-ad NGHyfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK2PWNxUUN3ME2xMlc{QDh5IN88US=> MknwV2FPT0WU
LB647-SCLC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwN{[1PFMh|ryP MX7TRW5ITVJ?
NCI-H2171 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ezcWlEPTB;MT63O|cyPiEQvF2= MnjKV2FPT0WU
SK-PN-DW MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzy[IVKSzVyPUGuPVEzQThizszN NGDhbWVUSU6JRWK=
MC-IXC Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nsdGlEPTB;MT65PFk5KM7:TR?= MX\TRW5ITVJ?
LS-513 MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDOXZpKSzVyPUKuNFU{ODVizszN Ml7zV2FPT0WU
EW-3 NHjqdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC4TWM2OD1{LkC5PFQ1KM7:TR?= NHPnTWhUSU6JRWK=
OPM-2 NFvXZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGyVYZFUUN3ME2yMlExOiEQvF2= M{\OT3NCVkeHUh?=
LP-1 NIX3[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfWTWM2OD1{LkK1PFA4KM7:TR?= NULMPHV4W0GQR1XS
LU-134-A MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;JemlEPTB;Mj6yO|ch|ryP NH3reY5USU6JRWK=
CP66-MEL NFG1PZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2cmlEPTB;Mj6yPVAyPCEQvF2= NITJPFVUSU6JRWK=
HCC1143 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LYe2lEPTB;Mj60OVM3QCEQvF2= MXnTRW5ITVJ?
LOXIMVI NHX1THNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M135dWlEPTB;Mj62NFIyKM7:TR?= NVTaWGlIW0GQR1XS
TE-10 M1TjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwN{C4N|gh|ryP NFTtTG9USU6JRWK=
NCI-H1882 NVPjUZp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInQTpRKSzVyPUKuO|UzOjdizszN Mo\RV2FPT0WU
CHP-126 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjmR4ZrUUN3ME2yMlc3OzF5IN88US=> M1fCTnNCVkeHUh?=
NCI-H1623 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTUcVBwUUN3ME2yMlkzODJ2IN88US=> NXXDOnkxW0GQR1XS
GB-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7STWM2OD1{LkmzOFA1KM7:TR?= NXq4cnlVW0GQR1XS
RCC10RGB NF7ZXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HjNGlEPTB;Mj65OVI5OSEQvF2= Mke2V2FPT0WU
NCI-H2141 M2WwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj4TWM2OD1{Lkm2PFk3KM7:TR?= NXX2foVJW0GQR1XS
GI-ME-N M17Jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP1TWM2OD1|LkCwOVY2KM7:TR?= NHfBVFRUSU6JRWK=
NCI-H526 NVnxOVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTNwMESwPFUh|ryP MYPTRW5ITVJ?
NCI-H747 M1PM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvJdopEUUN3ME2zMlA1QTl{IN88US=> NFm0XoRUSU6JRWK=
SNU-423 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXziUFZYUUN3ME2zMlIxOzF|IN88US=> MXXTRW5ITVJ?
A427 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\ubGlEPTB;Mz6yOVY6QSEQvF2= MX3TRW5ITVJ?
CAL-12T M3fWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jaOWlEPTB;Mz60NFcyOyEQvF2= M2HNfXNCVkeHUh?=
LU-99A NXTuTpA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTZTWM2OD1|LkS3NVA2KM7:TR?= MorMV2FPT0WU
MS-1 NGK5XIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3HVWxKSzVyPUOuOVM1OjlizszN MVXTRW5ITVJ?
SK-LU-1 M376WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\5OWlEPTB;Mz63OlI6PSEQvF2= MlH1V2FPT0WU
SW837 NFfwZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL4cItlUUN3ME2zMlc3OzN|IN88US=> MUXTRW5ITVJ?
ES8 NXnDcFZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInxPG9KSzVyPUOuPFM5PzdizszN M{GzR3NCVkeHUh?=
MZ2-MEL M37sTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTNwOUKwPFYh|ryP MWXTRW5ITVJ?
TGW NGLiSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTRwMEGzNVEh|ryP Ml\MV2FPT0WU
GP5d MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfLTWM2OD12LkC1N|YzKM7:TR?= MV7TRW5ITVJ?
BB49-HNC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDSTHBKSzVyPUSuNVUzOTNizszN NV3BbVU6W0GQR1XS
NB13 NUjXSG9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrzTWM2OD12LkK2PFg4KM7:TR?= MmHaV2FPT0WU
NTERA-S-cl-D1 M3T2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\2[GlEPTB;ND6yPFYyPSEQvF2= M1TCUHNCVkeHUh?=
NCI-H1648 M1HsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;DXYt5UUN3ME20MlI6QDF7IN88US=> M3LodnNCVkeHUh?=
LCLC-103H NVKye5dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS5dZBKSzVyPUSuN|IyQTVizszN MnfKV2FPT0WU
LS-411N NXrpXGZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTRwNES4PFUh|ryP MUXTRW5ITVJ?
NCI-H1092 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTRwNEW2PFch|ryP NVfzN4FWW0GQR1XS
PANC-10-05 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTRwNkm4OEDPxE1? MoroV2FPT0WU
DK-MG MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTRwOEC5N|Mh|ryP NF7Ve2ZUSU6JRWK=
OVCAR-5 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PrUWlEPTB;ND64NVIzPiEQvF2= NX;nV4xyW0GQR1XS
CAL-39 NVOwOYZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjVUZQ5UUN3ME20Mlg4PjdizszN NEHvU5FUSU6JRWK=
TE-441-T NUnSNmN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRwOUC1N|ch|ryP NIDSdGRUSU6JRWK=
MOLT-16 M2q1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwOUWyOVMh|ryP M2DmWnNCVkeHUh?=
MCF7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXVNI9XUUN3ME21MlE1PTF5IN88US=> NXPIS|RIW0GQR1XS
CAPAN-1 NIjrUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7o[VBKSzVyPUWuNlU4ODdizszN M3:5S3NCVkeHUh?=
PSN1 Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TxRmlEPTB;NT6yO|I{PSEQvF2= MofsV2FPT0WU
NCI-H292 NVvnXmx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS3WotTUUN3ME21MlMxODR2IN88US=> M3fqVnNCVkeHUh?=
CPC-N M{HURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrEfZE4UUN3ME21MlM6PDF7IN88US=> NEHJNWdUSU6JRWK=
DoTc2-4510 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS1UYZlUUN3ME21MlQ2OzdzIN88US=> MnzwV2FPT0WU
LB1047-RCC NHPsZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrEU2J4UUN3ME21MlU2QTN|IN88US=> NX\RZ2ZlW0GQR1XS
MHH-ES-1 M3G3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLMS4RZUUN3ME21MlU6QTB5IN88US=> NWjkdpRLW0GQR1XS
NMC-G1 NYf3UW9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPJWYVJUUN3ME21MlcxOjJ5IN88US=> MVXTRW5ITVJ?
SW1710 M{TMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXQOYdKSzVyPUWuO|Q4PTFizszN MWXTRW5ITVJ?
YAPC NFfGNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTVwN{[yNFEh|ryP NG\HSmhUSU6JRWK=
22RV1 M3PBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTVwOECwNVkh|ryP MWPTRW5ITVJ?
COLO-679 NGnObWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fIWGlEPTB;NT64PFk1QCEQvF2= NFfxWFBUSU6JRWK=
TCCSUP MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTVwOUOyOVkh|ryP NUD6T2FqW0GQR1XS
C2BBe1 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHYbVJjUUN3ME21Mlk{QTdizszN NEfiW2ZUSU6JRWK=
TE-15 NH\ITHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MniwTWM2OD14LkC2OlA2KM7:TR?= MXTTRW5ITVJ?
SCLC-21H MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHUW|JKSzVyPU[uNVA5PDNizszN NEe0fpdUSU6JRWK=
EoL-1-cell NWKyRVRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPrT5J3UUN3ME22MlE3PTZ|IN88US=> NEjhTGRUSU6JRWK=
NKM-1 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO0dG5KSzVyPU[uNVY4OSEQvF2= NXHWd|ZPW0GQR1XS
NCI-H1304 NYK5[oVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTZwMke0Nlgh|ryP MYLTRW5ITVJ?
NB6 M4jwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGez[GZKSzVyPU[uNlk3OjJizszN M{jRbnNCVkeHUh?=
NALM-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHvTnkxUUN3ME22MlM{OjNizszN NWf5VJVrW0GQR1XS
NCI-H522 NFHzOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7w[IlKSzVyPU[uN|M{ODZizszN NXzzZ5o5W0GQR1XS
MV-4-11 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXtTWM2OD14LkO3NFc6KM7:TR?= NHjzTYxUSU6JRWK=
LB2241-RCC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTZwM{i2Olch|ryP NIHxTXhUSU6JRWK=
NCI-H1417 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTZwNEC4OFch|ryP NWTuVmxyW0GQR1XS
HT-1197 NUXTW|BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\WUmlEPTB;Nj61O|EzOiEQvF2= NGXIPHRUSU6JRWK=
P30-OHK MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTZwNkK3O{DPxE1? M3TYeXNCVkeHUh?=
ALL-PO MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;ZNWJwUUN3ME22MlcyQTF4IN88US=> NWS3foY5W0GQR1XS
OVCAR-4 NV3Cd25iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTZwN{W0NFUh|ryP MmTnV2FPT0WU
HCC2157 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXkcZNKSzVyPU[uO|c1PzVizszN MorVV2FPT0WU
NCI-H838 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTZwOU[0PUDPxE1? NF76OoRUSU6JRWK=
NCI-H1299 NFG5cmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfuWZJKSzVyPU[uPVcxQSEQvF2= NEOwVoxUSU6JRWK=
SW954 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzaTWM2OD15LkKwNFY5KM7:TR?= MorGV2FPT0WU
NCI-H441 MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfWSIlKSzVyPUeuN|QxPjVizszN NF64WoJUSU6JRWK=
SK-MEL-2 NESzW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPoW2JKSzVyPUeuOFg{PzNizszN M{nGOHNCVkeHUh?=
KARPAS-45 NWrpN45JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDvfnNKSzVyPUeuOlU6OjlizszN NEC4cXRUSU6JRWK=
CAL-54 NIKyd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoezTWM2OD15LkiyPVc4KM7:TR?= NETid2VUSU6JRWK=
KYSE-180 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv2fWVKSzVyPUeuPFg6PDFizszN M2fXN3NCVkeHUh?=
NCI-H187 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7hcFl5UUN3ME23Mlk2QTR5IN88US=> NVH2OodlW0GQR1XS
RT-112 M164fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXiPGpKSzVyPUiuNFk3PzdizszN NGT0bYtUSU6JRWK=
NCI-H1437 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne2TWM2OD16LkC5O|k2KM7:TR?= NYLaVFhUW0GQR1XS
SNU-449 M4LoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7mNYhKSzVyPUiuNlgzPzJizszN MWLTRW5ITVJ?
HCC1187 M171dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HOd2lEPTB;OD6yPVM6OSEQvF2= NH74emlUSU6JRWK=
NCI-H2030 MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRThwM{e3NVQh|ryP Ml21V2FPT0WU
HuO-3N1 NVX3[VZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRThwM{e4OFQh|ryP MYPTRW5ITVJ?
COLO-792 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm0WG1KSzVyPUiuOFE2OjdizszN M3;RXnNCVkeHUh?=
MIA-PaCa-2 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGxTIhKSzVyPUiuPFU2ODhizszN MkP3V2FPT0WU
SK-N-FI NWfjflZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuwRYdKSzVyPUmuNFQzPSEQvF2= MYnTRW5ITVJ?
MMAC-SF NFi4enFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrVTWM2OD17LkC5O|UyKM7:TR?= MoLyV2FPT0WU
NCI-H28 NF3QfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTlwMUC0Olkh|ryP M1nPPXNCVkeHUh?=
ETK-1 NWfUdFVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[1dWlEPTB;OT6yPVk4PCEQvF2= NUP0PIF5W0GQR1XS
NCI-H1993 NWfRUnJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDxTWM2OD17LkS0NlYyKM7:TR?= M4[1ZXNCVkeHUh?=
no-11 MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjGT|FnUUN3ME25MlQ4OTJizszN NWjTWJFkW0GQR1XS
ChaGo-K-1 NUPhfZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\PdnRKSzVyPUmuOVE2QDNizszN Ml;pV2FPT0WU
NCCIT Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfxPVlFUUN3ME25MlU{OTZ7IN88US=> MmfsV2FPT0WU
SAS NXW2VJd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXGTWM2OD1zMD6yOFgh|ryP MmT6V2FPT0WU
A673 Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rR[2lEPTB;MUCuN|cxPCEQvF2= Ml60V2FPT0WU
NCI-H1522 NFjPVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[2TWM2OD1zMD6zO|A4KM7:TR?= MWHTRW5ITVJ?
NCI-H810 NUXpN|VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HkN2lEPTB;MUCuN|kxPyEQvF2= NX;xbGRxW0GQR1XS
IST-MES1 M4TPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:4TWM2OD1zMD60OVY1KM7:TR?= M2[5SHNCVkeHUh?=
GR-ST NXWyTVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGzVZFKSzVyPUGwMlUxOjRizszN MVXTRW5ITVJ?
SUP-T1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6yOppKSzVyPUGwMlc{OTdizszN NXr5dWEzW0GQR1XS
NB5 NV\qc|U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHMTWM2OD1zMD65NFIzKM7:TR?= M3TsSnNCVkeHUh?=
MZ1-PC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD3Z4tyUUN3ME2xNE46PTdzIN88US=> NU\JNVVSW0GQR1XS
SK-CO-1 NIHXNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PGeWlEPTB;MUCuPVk{OSEQvF2= MmTHV2FPT0WU
Capan-2 M4jkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq1N3RLUUN3ME2xNU4{OTl6IN88US=> NHK4[FBUSU6JRWK=
697 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFeyUW9KSzVyPUGxMlY4PTdizszN MmTMV2FPT0WU
REH M{LITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfHTWM2OD1zMT63OFUyKM7:TR?= NYXjc5psW0GQR1XS
GI-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFzLki2NVUh|ryP NFnxUZNUSU6JRWK=
BB65-RCC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF{LkC5NVYh|ryP MUDTRW5ITVJ?
NCI-H1651 NXKzXVdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj6Vlc1UUN3ME2xNk4zPDd6IN88US=> MnO1V2FPT0WU
NCI-H1618 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\vTWM2OD1zMj6zPVc3KM7:TR?= M1;sb3NCVkeHUh?=
NCI-H2081 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn0TWM2OD1zMj62NVQyKM7:TR?= NFe1c4lUSU6JRWK=
GCIY MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF{LkeyNVMh|ryP MVfTRW5ITVJ?
NY M2nMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF|LkC2OFMh|ryP MXHTRW5ITVJ?
PANC-03-27 M2HlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3jTGI{UUN3ME2xN{4xQDB5IN88US=> NFTGcGNUSU6JRWK=
BHY NHn1UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW2TWM2OD1zMz6yNVIyKM7:TR?= M4HDR3NCVkeHUh?=
SK-OV-3 NH25RXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPWe|MyUUN3ME2xN{4{PzZ|IN88US=> Mk\sV2FPT0WU
5637 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWno[JY1UUN3ME2xN{44PzV7IN88US=> MljaV2FPT0WU
LC-1F MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrHUpNGUUN3ME2xOE4xOzV4IN88US=> MkXFV2FPT0WU
SNB75 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XJeWlEPTB;MUSuNFM5OyEQvF2= M1rpfXNCVkeHUh?=
CHP-212 M{fHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nvVmlEPTB;MUSuNFQ3PCEQvF2= MYLTRW5ITVJ?
HT-1376 M33Ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF2LkGxNlYh|ryP M2O4fXNCVkeHUh?=
MONO-MAC-6 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXFbXh3UUN3ME2xOE4yPTB{IN88US=> M{TySXNCVkeHUh?=
CA46 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF2LkG4Nlch|ryP M1[wTHNCVkeHUh?=
SCC-15 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjtb2NVUUN3ME2xOE42PTh|IN88US=> M1zVN3NCVkeHUh?=
ATN-1 NVj3[Ix5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDHd4ZKSzVyPUG0MlY3OjdizszN MoDIV2FPT0WU
NCI-H2405 NEHpc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF2LkixOVch|ryP M2rwW3NCVkeHUh?=
NCI-H716 NVPaS3A{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\KUZVKSzVyPUG0Mlg1QTNizszN NXi4[25XW0GQR1XS
SW620 M2rubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTlVlhKUUN3ME2xOE46ODF2IN88US=> NYfjSnhNW0GQR1XS
NCI-H226 NXn0Z4NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjaeItKSzVyPUG0MlkxQDVizszN NVrlWmZsW0GQR1XS
SW962 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vIUWlEPTB;MUSuPVQ{OiEQvF2= MXjTRW5ITVJ?
KYSE-150 M2\L[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF2Lkm1OUDPxE1? MkLzV2FPT0WU
OCUB-M Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MniwTWM2OD1zND65PFg{KM7:TR?= NX7SVG8{W0GQR1XS
ES7 NXfjeoZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P4bWlEPTB;MUWuNFk5PCEQvF2= MUTTRW5ITVJ?
SW1463 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF3LkSyNlMh|ryP NVXQVYhUW0GQR1XS
CAKI-1 NVjnS2F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3tN|kyUUN3ME2xOU42OzR4IN88US=> MojUV2FPT0WU
MKN28 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF3LkW0O|kh|ryP NYj2S5M2W0GQR1XS
SW13 NHS5cY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHRb3pxUUN3ME2xOU43OThizszN NX3mWHF5W0GQR1XS
A3-KAW NH7RVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\KUGlEPTB;MUWuPVY6PyEQvF2= NFL5[4RUSU6JRWK=
LU-65 NHraSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\sPWZKSzVyPUG1Mlk4PjhizszN MYrTRW5ITVJ?
Calu-1 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nUNGlEPTB;MU[uNFM3QCEQvF2= NXLqR485W0GQR1XS
ST486 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy2WJJIUUN3ME2xOk4xPDNzIN88US=> MVPTRW5ITVJ?
BB30-HNC MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTF4LkGyOFYh|ryP NWPjdmhJW0GQR1XS
EGI-1 NX;ncJBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr6TWM2OD1zNj60OFYh|ryP NGL5O5ZUSU6JRWK=
SH-4 NY\NfIViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHUSYJKSzVyPUG2MlQ4OzFizszN MWHTRW5ITVJ?
MN-60 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF5LkKyPVch|ryP NFXXS4ZUSU6JRWK=
MPP-89 M1y3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn25TWM2OD1zNz6yOFU6KM7:TR?= MlP6V2FPT0WU
A2780 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\0WWk4UUN3ME2xO{41OTN7IN88US=> MmC3V2FPT0WU
Daoy MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonBTWM2OD1zNz60Olk2KM7:TR?= MnW3V2FPT0WU
NCI-H2126 NWLFPIVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETOUXVKSzVyPUG3MlQ4PzFizszN NGXqO5VUSU6JRWK=
NCI-H1563 NIrOOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHhOJhDUUN3ME2xO{41QTF5IN88US=> MmDTV2FPT0WU
8-MG-BA M{Tie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX6xTpNjUUN3ME2xO{43PjR6IN88US=> MVnTRW5ITVJ?
786-0 M1;FXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHIeJpQUUN3ME2xO{45OzV|IN88US=> NVq3NpFPW0GQR1XS
AM-38 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\zTmlEPTB;MUeuPVMxPiEQvF2= NVnJUnR3W0GQR1XS
COLO-824 M4iw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\wTYFKSzVyPUG4MlQ1OzZizszN NFHjWHlUSU6JRWK=
SK-MEL-30 NWH2eZp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13GWmlEPTB;MUiuOVA5OiEQvF2= M2T2N3NCVkeHUh?=
CESS NXGzWWJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF6Lke2NFkh|ryP NI[5N2NUSU6JRWK=
BL-70 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnTXIpmUUN3ME2xPE45OTV4IN88US=> M3rkfnNCVkeHUh?=
NCI-H2170 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P4[GlEPTB;MUiuPVE4QSEQvF2= Mln6V2FPT0WU
HT-3 MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL4RoNKSzVyPUG4Mlk5OyEQvF2= NY\rRWl2W0GQR1XS
BOKU NX[zfldCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF7LkCzPFEh|ryP Mm\nV2FPT0WU
HPAF-II M4LtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLyZZVsUUN3ME2xPU4{ODF3IN88US=> M121[XNCVkeHUh?=
KGN Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjwTWM2OD1zOT60O|Y2KM7:TR?= NHzBU4FUSU6JRWK=
MC-CAR NXnJUZBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HwUGlEPTB;MUmuOlMyOyEQvF2= NFf6R4dUSU6JRWK=
BHT-101 NGLHRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF7Lke3O{DPxE1? MWPTRW5ITVJ?
SW1783 MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF7Lke4NFYh|ryP M4rqRnNCVkeHUh?=
KP-N-YN M3LMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJyLkCyOlIh|ryP MXHTRW5ITVJ?
LU-165 NEHpSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJyLkW1O|Eh|ryP M1zDSHNCVkeHUh?=
GOTO NHnTUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlniTWM2OD1{MD62OFUyKM7:TR?= MVnTRW5ITVJ?
EFM-19 NXvxR2pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj6[nNTUUN3ME2yNU4xPzF4IN88US=> MWjTRW5ITVJ?
CTV-1 M1\QWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LvW2lEPTB;MkGuNVA2PCEQvF2= NW\IPHNtW0GQR1XS
HEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjXfFhKSzVyPUKxMlQzOTZizszN NVOxZWF7W0GQR1XS
SNU-C2B MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zuXmlEPTB;MkGuOFI3KM7:TR?= M2f2SnNCVkeHUh?=
ECC4 NXr1NXQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJzLkewO{DPxE1? MnzrV2FPT0WU
NEC8 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fBcGlEPTB;MkGuPFM3QCEQvF2= NGfxTHpUSU6JRWK=
KMOE-2 NEL4dGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL5NmFKSzVyPUKxMlg6OjFizszN MWfTRW5ITVJ?
NCI-H524 NWT2RZgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\COHlKSzVyPUKyMlA5ODhizszN NITDS3FUSU6JRWK=
WSU-NHL NHvvSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG0Zo1KSzVyPUKyMlE2PzdizszN MkPUV2FPT0WU
SF126 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPsTWM2OD1{Mj6yOFY6KM7:TR?= NFjLe5ZUSU6JRWK=
HOP-92 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLnTWM2OD1{Mj6zNVY4KM7:TR?= NVz0OJJvW0GQR1XS
CTB-1 NVHHUZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTSN|MzUUN3ME2yNk41Pjd5IN88US=> M4DCRXNCVkeHUh?=
KYSE-270 NWjGb4J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TVV2lEPTB;MkKuPVM2PyEQvF2= NH\qR4ZUSU6JRWK=
SK-MEL-24 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfKfW14UUN3ME2yN{4yQDdizszN MX\TRW5ITVJ?
Calu-3 NFyzUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DLO2lEPTB;MkOuNlEzQCEQvF2= MoP1V2FPT0WU
GAMG MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\U[2RIUUN3ME2yN{4zOzZ5IN88US=> NHPVXYFUSU6JRWK=
SW1573 NXTlWHBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[yTWM2OD1{Mz63OFE2KM7:TR?= Mo\DV2FPT0WU
MHH-NB-11 M4TrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\XWmlEPTB;MkSuNFE6PCEQvF2= NUDscoZ3W0GQR1XS
TK10 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PoRmlEPTB;MkSuOVAyOyEQvF2= NWe4SXR4W0GQR1XS
LB373-MEL-D NE\qNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzWTWM2OD1{ND62NFY1KM7:TR?= NYfBdotKW0GQR1XS
KALS-1 NYf5NZU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XjWWlEPTB;MkSuO|MzPyEQvF2= M3PRNHNCVkeHUh?=
HUTU-80 M4TjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7VNodKSzVyPUK1MlgxOzJizszN M{nQb3NCVkeHUh?=
HuP-T3 NFLKfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fWXGlEPTB;Mk[uNVY4PCEQvF2= NYDu[m4{W0GQR1XS
OE19 NXPPXHlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCxTWM2OD1{Nj6yNVU{KM7:TR?= NGK5V41USU6JRWK=
J82 M3LLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDTTWM2OD1{Nj6yOFcyKM7:TR?= NXuwc4dxW0GQR1XS
DU-4475 NHi1XHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LEdWlEPTB;Mk[uN|gyQSEQvF2= Mn3WV2FPT0WU
DMS-53 M4LrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vSfmlEPTB;Mk[uOVE{QCEQvF2= NELYR5NUSU6JRWK=
COLO-741 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUKzPVJHUUN3ME2yOk45OzR2IN88US=> MlzCV2FPT0WU
SW48 NIfK[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\rWmVKSzVyPUK2Mlg5OiEQvF2= MlHWV2FPT0WU
IGR-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ4LkmzN|Qh|ryP MXrTRW5ITVJ?
639-V NHPiSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn3TWM2OD1{Nz6wNlQ2KM7:TR?= MULTRW5ITVJ?
LK-2 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf3cI45UUN3ME2yO{41OTRzIN88US=> NHLBfmVUSU6JRWK=
NCI-H2347 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7WTWM2OD1{Nz65Olk6KM7:TR?= M1rsZnNCVkeHUh?=
NCI-H2228 NXPLe5RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv3TWM2OD1{OD6wPVA2KM7:TR?= NXm0[o1GW0GQR1XS
LS-123 NFHCZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HJfGlEPTB;MkiuNVI3OiEQvF2= NUXBdHpLW0GQR1XS
U031 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\OTWM2OD1{OD6yOVIh|ryP Mkf2V2FPT0WU
NCI-H1792 NGrQSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXPRWZUUUN3ME2yPE41PzJzIN88US=> NHnpfmJUSU6JRWK=
NCI-H2087 M3fjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnidWdbUUN3ME2yPE44PTV{IN88US=> M2PZTHNCVkeHUh?=
NCI-H2342 NXHm[WN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDtUW82UUN3ME2yPU42OjB6IN88US=> NFnVNHpUSU6JRWK=
SW626 NGWydXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHWd|NKUUN3ME2yPU44PTZizszN Mn23V2FPT0WU
LB2518-MEL NVq4ZpdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\sNVNKSzVyPUK5MlgyPSEQvF2= MWDTRW5ITVJ?
RXF393 M4[zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\sV2lEPTB;M{CuNFk2OiEQvF2= MorOV2FPT0WU
LC4-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITHboNKSzVyPUOwMlMxQTJizszN NYTPVm9TW0GQR1XS
NCI-H1694 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3HSIprUUN3ME2zNE43PjJ2IN88US=> NGHmTlhUSU6JRWK=
K5 NEXYU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TBWWlEPTB;M{CuPVcxOiEQvF2= MVvTRW5ITVJ?
HDLM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjIUpZ1UUN3ME2zNE46PzJ3IN88US=> M3mwc3NCVkeHUh?=
BCPAP NVraSXE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPvdGljUUN3ME2zNU45Ozd7IN88US=> MVLTRW5ITVJ?
BC-3 NYjhbJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN{LkG0NFMh|ryP MkfDV2FPT0WU
LB996-RCC MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojiTWM2OD1|Mj6yN|U5KM7:TR?= MnPqV2FPT0WU
NCI-H2009 NITGR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTN{LkS5PFEh|ryP MVHTRW5ITVJ?
HTC-C3 NYHab2x2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX5c3YzUUN3ME2zN{44PTF7IN88US=> NF7Kc5dUSU6JRWK=
LAMA-84 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojJTWM2OD1|ND60OFA4KM7:TR?= M1zVWHNCVkeHUh?=
CCRF-CEM M17Hbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK1dlM5UUN3ME2zOE42PzF3IN88US=> MVfTRW5ITVJ?
AN3-CA NYnBToRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN3LkC1Olgh|ryP MVjTRW5ITVJ?
NCI-H1734 M1jKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO0U4JSUUN3ME2zOU4zPTZzIN88US=> Mlf0V2FPT0WU
Ca-Ski MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn2NYJKSzVyPUO1MlQyODFizszN MXvTRW5ITVJ?
U-266 NV3Cd|BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O0fmlEPTB;M{WuOlEyPCEQvF2= NVTpZWVGW0GQR1XS
SBC-5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnmNZZuUUN3ME2zOU44PzhzIN88US=> MU\TRW5ITVJ?
GT3TKB Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTN5LkGxOUDPxE1? MlfOV2FPT0WU
MDA-MB-175-VII NH\iWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzIcW1SUUN3ME2zO{4zOjR6IN88US=> MoXHV2FPT0WU
PFSK-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz5XJB1UUN3ME2zO{4zPDN3IN88US=> NYrUeJl6W0GQR1XS
IMR-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXETWM2OD1|Nz6yOFg4KM7:TR?= MX;TRW5ITVJ?
Daudi NX7qe5JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTQRVhKSzVyPUO3MlM2QTdizszN MlfSV2FPT0WU
A498 NV;kW4ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnneXdKSzVyPUO3MlczOThizszN MUfTRW5ITVJ?
SCC-4 M4TjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Pwd2lEPTB;M{euO|g1OyEQvF2= NIPLdFNUSU6JRWK=
COLO-680N NInMbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnycIFWUUN3ME2zPE4zQDh3IN88US=> MX;TRW5ITVJ?
SK-MES-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN6LkOyNVUh|ryP NWO3bpVKW0GQR1XS
SR MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\WSWlEPTB;M{iuOVQ6PSEQvF2= MlTHV2FPT0WU
LNCaP-Clone-FGC MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HvNmlEPTB;M{iuOVY{PyEQvF2= MnTIV2FPT0WU
SK-HEP-1 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4CyVmlEPTB;M{iuO|gzOiEQvF2= NWSyN3lOW0GQR1XS
BPH-1 NEnuNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XkcmlEPTB;M{iuPFMzQSEQvF2= NVzTU4FVW0GQR1XS
NCI-H1755 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT0UHk2UUN3ME2zPU42QDF5IN88US=> M2m2c3NCVkeHUh?=
LXF-289 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq4RnBKSzVyPUO5MlgxQDRizszN NHqwZlNUSU6JRWK=
SW1088 NU\tfllYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrxN|d3UUN3ME20NE4zOTB5IN88US=> MUnTRW5ITVJ?
MOLT-4 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTRyLkK5NFEh|ryP MlzLV2FPT0WU
AsPC-1 M1LlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDJTWM2OD12MD60OVg{KM7:TR?= MkfaV2FPT0WU
HOP-62 NETMc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjPVZJKSzVyPUSwMlY2PjhizszN M3Kz[XNCVkeHUh?=
A172 NW\mPVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n5RWlEPTB;NECuPFUyOSEQvF2= NXHER|NFW0GQR1XS
SN12C M3jQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG2PWFSUUN3ME20NE46Ozh3IN88US=> MmiyV2FPT0WU
MDA-MB-231 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HMc2lEPTB;NECuPVg6QCEQvF2= MWnTRW5ITVJ?
RPMI-2650 M3;0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nPOGlEPTB;NEGuNVU6OyEQvF2= M4XiUXNCVkeHUh?=
KYSE-140 M3rHOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LjXGlEPTB;NEGuPFEzOyEQvF2= MVHTRW5ITVJ?
KINGS-1 NYSzenZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHBTW1RUUN3ME20Nk41Pjl5IN88US=> NYj2TGdMW0GQR1XS
HSC-3 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnxTWVZUUN3ME20Nk43PjZzIN88US=> MWXTRW5ITVJ?
PC-14 MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvlUYdKSzVyPUSzMlE5QDJizszN NGexVllUSU6JRWK=
COR-L105 M1;mVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PvZWlEPTB;NEOuOlUxOiEQvF2= NV;3[4YzW0GQR1XS
BE-13 M1rEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTjTWM2OD12ND6yN|cyKM7:TR?= MlXWV2FPT0WU
NCI-H661 NEG5[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTR2LkK5OVgh|ryP MkfPV2FPT0WU
IST-MEL1 NFvWeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzoRZNKSzVyPUS0MlM2QTlizszN MVfTRW5ITVJ?
HCC1806 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrnOoNKSzVyPUS0MlU5PzNizszN M{DxcHNCVkeHUh?=
COLO-800 NWK3VFVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXKxTI1[UUN3ME20OE45PDV|IN88US=> NWf0flFJW0GQR1XS
IST-SL2 Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR3LkGyOFch|ryP M2qwbnNCVkeHUh?=
8305C MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7OXIRmUUN3ME20OU4{ODlizszN M1fjNHNCVkeHUh?=
UACC-62 NYCyblQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPLRZRUUUN3ME20Ok4zQDd3IN88US=> MVHTRW5ITVJ?
COR-L23 M1\BW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;jbmlEPTB;NEeuNVk6KM7:TR?= M1;nZXNCVkeHUh?=
EFE-184 NHL4TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4iwfWlEPTB;NEeuN|g5KM7:TR?= M4jVOHNCVkeHUh?=
DMS-114 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DPVmlEPTB;NEeuOFE1QSEQvF2= MknsV2FPT0WU
KYSE-520 NEP5WVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPOTWM2OD12OD61N|E2KM7:TR?= NEPiUYpUSU6JRWK=
SNG-M NXn2Oo4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Xw[2lEPTB;NEmuOFM1KM7:TR?= NXW4XYRqW0GQR1XS
A2058 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;ibFlEUUN3ME20PU41QDh3IN88US=> NFSxfINUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型,抑制肿瘤生长,按 75 mg / kg剂量处理,导致100% TGI和 55% 衰退,按25 mg/kg剂量处理,导致 60% TGI,没有衰退。OSI-906处理犬,大鼠和小鼠,诱导不同的消除半衰期,消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠,每天一次,Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天,提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型,在4 和24小时间最大程度抑制IGF-IR磷酸化(80%),血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠,处理2,4,24小时,抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型,抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中,使用聚 (Glu:Tyr)作为底物,结合到96孔实验板表面,使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物,通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中,人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白,且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验,除非另有说明,取三次测量的最小值。
细胞实验:[1]
+ 展开
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖,细胞接种在含FCS 10%的合适培养基上,在不同浓度OSI-906存在时,温育3天。通过细胞内ATP含量的荧光量化,使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分,通过在不同浓度 OSI-906存在时的细胞密度除以对照组(只用DMSO处理)细胞密度。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Formulation: 25 mM 酒石酸
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理,每天一次,持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O

CAS号 867160-71-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01186861 Completed Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy Astellas Pharma Inc March 4 2011 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品

Tags: 购买Linsitinib (OSI-906) | Linsitinib (OSI-906)供应商 | 采购Linsitinib (OSI-906) | Linsitinib (OSI-906)价格 | Linsitinib (OSI-906)生产 | 订购Linsitinib (OSI-906) | Linsitinib (OSI-906)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID